Simcha Therapeutics
About
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Overview
Pipeline
Publications
Patients
Culture & Careers
Partnering
News
Press Releases
Media
Contact
Engineering a better immunotherapy to outwit cancer — and launch a biotech
Simcha debuts with $25M to advance custom-built IL-18 for cancer
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
MENU
About
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Overview
Pipeline
Publications
Patients
Culture & Careers
Partnering
News
Press Releases
Media
Contact